

Mathieu COLLOMB<sup>1</sup>, Hélène CHEVALLARD<sup>1</sup>, Claire CHAPUIS<sup>1</sup>, Luc FORONI<sup>1</sup>, Jean CALOP<sup>1,2</sup>, Benoit ALLENET<sup>1,2</sup>, Pierrick BEDOUCH<sup>1,2</sup>

1 : Pôle Pharmacie, CHU de Grenoble  
2 : UJF-Grenoble 1/CNRS / TIMC-IMAG UMR 5525 / Themis, UJF

## INTRODUCTION


Treprostinil is a prostacyclin analogue indicated in the treatment of Pulmonary Arterial Hypertension (PAH) for patients with functional NYHA class III. The administration is a continuous subcutaneous infusion. The recommended initiation of treatment is in intensive care with a dosage adjustment increments to a target dose.

Injection site's pain and local reactions (respectively 85% and 83% of patients) cause cessation of treatment in 8% of cases<sup>1</sup>.



A descriptive study of a patient having pain after subcutaneous injection of treprostinil was conducted. We collected information from clinical and pharmacotherapeutic history. A systematic literature about practical considerations on subcutaneous treprostinil in pulmonary arterial hypertension was performed. At Grenoble's Hospital, management of pain due to Treprostinil includes an activity of therapeutic education managed by pharmacist, doctor, nurse belonging to different units (pharmacy, pneumology, pain's mobile team...).

## CASE



## CONCLUSION

- Intense pain due to Treprostinil may require discontinuation of effective treatment.
- This case shows that multidisciplinary care with the application of simple measures allows to manage this common side effect and to avoid the cessation of treatment.

## REFERENCES

<sup>1</sup> Mathier MA, McDevitt S, Saggarr R. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. J Heart Lung Transplant. 2010; 29: 1210-7  
<sup>2</sup> Bedouch et al. Pharmacists involved in patient education: a pharmacist collaborative care program for pulmonary arterial hypertension. Int J Clin Pharm. 2011; 33: 898-901